TriangleNilotinib and Paclitaxel (NCT04449549)
Nilotinib and Paclitaxel trial for Neoplasms (NCT04449549). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people aged 18–120 with advanced adult granulosa-cell ovarian cancer, clear-cell ovarian cancer, anal cancer or Ewing sarcoma. Cancer must progress after standard therapy, or no standard option must exist.
The idea: combine nilotinib, a BCR-Abl kinase blocker, with paclitaxel, which disrupts cell division. Nilotinib is taken twice daily; paclitaxel infusions occur on days 1, 8 and 15 of each 28-day cycle. Researchers measure tumor response. Biopsies are optional. Other rare cancers are ineligible.
This phase 2 study plans 82 patients. Alice Chen leads at NIH’s recruiting Bethesda site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.